Saniona AB (publ) (OM: SANION)
Health Care · Biotechnology · DK
Skr12.02
-6.75% today · -2.1% 1Y
Saniona AB (publ) (OM: SANION) operates in the Biotechnology industry within the Health Care sector. The company is valued at $175.21M and employs 43 people.
Over the last twelve months the share price has lost 2.1%, trading between 11.00 and 28.30.
Tweenvest scores Saniona AB (publ) across four factors: quality 74/100, value 42/100, growth 100/100. Its strongest factor is growth.
SANION price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $175.21M
- Revenue (TTM)
- $45.11M
- P/E
- 7.52
- EPS
- 1.60
- Dividend yield
- —
- Beta (5Y)
- 1.22
- 52-week high
- Skr28.30
- 52-week low
- Skr11.00
- Avg volume (3M)
- —
- Shares outstanding
- 138.03M
- Employees
- 43
- Next earnings
- —
About Saniona AB (publ)
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
- ISIN
- SE0005794617
- Founded
- 2011
- Listed since
- Apr 22, 2014
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.40 | -1.28% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.34 | -0.20% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $149.27 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.09 | -0.50% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $824.00 | -1.15% |
| argenx SEENXTBR: ARGX | $64.17B | €889.60 | +1.18% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.54 | -5.85% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.